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Abstract
The nuclear receptor co-repressor (N-CoR) is a key component of the generic multi-protein complex involved in
transcriptional control. Flt3, a key regulator of hematopoietic cell growth, is frequently deregulated in AML (acute myeloid
leukemia). Here, we report that loss of N-CoR-mediated transcriptional control of Flt3 due to misfolding, contributes to
malignant growth in AML of the M5 subtype (AML-M5). An analysis of hematopoietic genes in AML cells led to the
identification of Flt3 as a transcriptional target of N-CoR. Flt3 level was inversely related to N-CoR status in various leukemia
cells. N-CoR was associated with the Flt3 promoter in-vivo, and a reporter driven by the Flt3 promoter was effectively
repressed by N-CoR. Blocking N-CoR loss with Genistein; an inhibitor of N-CoR misfolding, significantly down-regulated Flt3
levels regardless of the Flt3 receptor mutational status and promoted the differentiation of AML-M5 cells. While stimulation
of the Flt3 receptor with the Flt3 ligand triggered N-CoR loss, Flt3 antibody mediated blockade of Flt3 ligand-receptor
binding led to N-CoR stabilization. Genetic ablation of N-CoR potentiated Flt3 ligand induced proliferation of BA/F3 cells.
These findings suggest that N-CoR-induced repression of Flt3 might be crucial for limiting the contribution of the Flt3
signaling pathway on the growth potential of leukemic cells and its deregulation due to N-CoR loss in AML-M5, could
contribute to malignant growth by conferring a proliferative advantage to the leukemic blasts. Therapeutic restoration of N-
CoR function could thus be a useful approach in restricting the contribution of the Flt3 signaling pathway in AML-M5
pathogenesis.
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Introduction
Acute Monoblastic/Monocytic leukemia (AML-M5) is a class of
Acute Myeloid Leukemia (AML) classified under the M5 subtype
in the French-American-British (FAB) classification. It is defined as
a group of malignant disorder characterized by the abnormal
accumulation of immature cells of the myelo-monocytic lineage in
the bone marrow and peripheral blood [1,2] and constitutes about
5 to 10% of all AML cases in adult humans. Although the fusion
oncogene MLL1-AF9 is mainly associated with AML-M5 [3,4], it
is not the only genetic anomaly present and other diverse genetic
aberrations are also reported in the disease [5]. However, despite
the varied genetic background of the disease, the phenotypic
presentation is almost identical, characterized by the differentia-
tion arrest at the monoblast and/or promonocytic stage coupled
with increased survival and proliferation capacities: a hallmark of
AMLs. Thus it is thought that aberrations involving key
transcription factors and its associated co-activators and co-
repressors essential for the differentiation process are major driving
forces of AML-M5 pathogenesis.
One such factor is the nuclear receptor co-repressor (N-CoR), a
key component of the multi-protein co-repressor complex involved
in transcriptional repression mediated by various transcriptional
factors. N-CoR was first identified as a co-repressor of un-liganded
nuclear hormone receptors [6,7] and was later demonstrated to be
essential for the transcriptional repression mediated by Mad and
other sequence-specific transcription factors [8,9]. It was later
identified as a Ski interacting protein in yeast two-hybrid assay
[10] and was also demonstrated to have an essential role in the
transcriptional repression of the tumor suppressors Mad and Rb
[11,12]. Our laboratory later reported that abrogation of N-CoR-
mediated transcriptional repression due to a misfolded conforma-
tion dependent loss (MCDL) of N-CoR protein was associated
with the differentiation arrest of leukemic cells in Acute
Promyelocytic Leukemia (APL) [13,14,15]. Recently, N-CoR
was also reported to be essential for the differentiation of erythroid
cells [16]. These findings coupled with reports indicating that N-
CoR knockout mice were embryonically lethal and appeared to
die from anemia due to defects in definitive erythropoiesis [17],
highlighted an essential role of N-CoR in the differentiation of cells
during myeloid lineage commitment.
The cytokine receptor FMS-Like Tyrosine Kinase III (Flt3) is a
membrane bound receptor tyrosine kinase (RTK) belonging to the
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It is a key factor that maintains immature hematopoietic cells in an
undifferentiated state by promoting their self-renewal and
proliferative potentials [19,20] and is expressed in majority of
the human and mice repopulating hematopoietic stem cell (HSC)
population [19,21]. Involvement of Flt3 in the proliferation of
HSCs and early progenitor cells suggests that Flt3 expression and
activation of the Flt3 signaling pathway have possible oncogenic
potentials. Evidence from clinical studies has indicated that Flt3
has the capacity to enhance survival and proliferation of leukemic
blasts, with a high percentage of AMLs expressing Flt3 [22,23,24].
A contributing role of Flt3 in the transforming potential of PML-
RARa and various MLL1 fusion proteins have been identified in
several mice models of APL and AML-M5 [25,26,27,28,29,30].
However the exact nature of this co-operation in the malignant
growth and transformation of APL and AML-M5 cells is not
known. Here we report that Flt3 (regardless of its mutational
status) is a target of N-CoR mediated transcriptional repression
and demonstrate how aberrant expression of the Flt3 receptor due
to a post-translational loss of N-CoR contributes to the survival
and growth advantage of leukemic cells in AML-M5. We also
show that therapeutic restoration of N-CoR in AML-M5 cells may
be a useful approach in restricting the role of Flt3 mediated
survival and proliferative capacity in leukemic blasts.
Materials and Methods
AML cell lines, primary AML samples and reagent
The AML-M5 cell lines, THP-1, Mono-Mac-1 (MM1), Nomo-
1, MV-4-11, non-AML-M5 cell lines U937, HL-60, K562 and
APL cell line NB4 were maintained in RPMI 1640 medium (Life
Technologies, Gaithersburg, MD) supplemented with 10% Fetal
Bovine Serum (FBS; Hyclone Laboratories, Logan, UT), in a
humidified atmosphere of 5% CO2. The AML-M5 cell line SigM5
was maintained in Isocove’s modified medium (Life Technologies,
Gaithersburg, MD) supplemented with 20% FBS while 293T cells
were maintained in DMEM (Sigma Aldrich, MO, USA) enriched
with 10% FBS. BA/F3 cells were maintained in RPMI 1640
medium supplemented with 10% FBS and 10 ng/ml recombinant
mouse IL-3 (R&D systems, MN, USA). Cell lines were purchased
from ATCC (Manassas, VA, USA), DSMZ - Deutsche Sammlung
von Mikroorganismen und Zellkulturen GmbH (German Collec-
tion of Microorganisms and Cell Cultures, Germany) and Japan
Health Sciences Foundation (Osaka, Japan).
Primary leukemic samples used in this study were obtained at
the time of diagnosis. Diagnoses of AML were made from the
morphology and cytochemistry according to the French–Ameri-
can–British (FAB) classification as well as immunophenotypic and
cytogenetic analyses. This study was approved by the Institutional
Review Boards of National University of Singapore. Informed
consent was obtained from the patients in accordance with the
Declaration of Helsinki.
The N-CoR [C-20] (goat polyclonal) antibody was purchased
from Santa Cruz Biotechnology (California, USA) and used as
described previously [14,15]. Flt3 (C-20) and Flt3 (8H5) antibodies
were from Santa Cruz Biotechnology (California, USA) while
FITC-conjugated CD14 antibody was from BD Pharmingen (San
Diego, CA, USA). N-CoR stabilizing agent Genistein (Sigma
Aldrich, MO,USA) was used as previously described elsewhere
[15].
Real-time PCR assay
Total RNA was isolated using the RNeasy Mini Kit (Qiagen
GmBH, Hilden, Germany). From each sample, 2 mg of RNA was
converted into cDNA by oligo (dT)18-primed reverse transcription
using SuperScript II RT First-Strand kit (Invitrogen, Carlsbad,
CA, USA) as described by the manufacturer. First-strand cDNA
was synthesized using SMART-PCR cDNA Synthesis Kit
(Clontech). Real-time PCR analysis was carried out using the
TaqmanH Gene Expression Assay System (Applied Biosystems,
CA, USA) and Ct values were recorded using the ABI Prism 7300
Real Time PCR system (Applied Biosystems, CA, USA).
Analysis of Real-Time PCR data
For gene expression in cell lines, data was analyzed using the
comparative Ct method where the cell line HL-60 was used as the
reference sample and the HPRT gene was used as the endogenous
gene control. Data representation for gene expression analysis is in
the form of a bar graph plotted on a logarithmic scale with a base
of 10, where expression level in the reference sample for all genes
was set to 0 while genes which were up regulated relative to
expression levels in the reference sample was given a positive value
and those which are down regulated relative to expression levels in
the reference sample was given a negative value. Raw Ct values
that registered as undetermined were given a value of to 40 for the
purpose of calculation and analysis. Data represented is the
average obtained from 3 independent experiments.
RT-PCR analysis
cDNA was subject to RT-PCR analysis using Accuprime Taq
polymerase system (Invitrogen, Carlsbad, CA, USA) according to
manufacturer’s recommendations. The sequence of the primers is
presented in Table S1.
RNA interference
All siRNA (Qiagen, Hilden, Germany) were synthesized as fully
annealed oligonucleotide duplexes. For siRNA-mediated knock-
down of N-CoR in HL-60 cells, 2 mg of siRNA was transfected by
electroporation using the Cell Line Nucleofector Kit V (Amaxa,
Cologne, Germany) according to the manufacturer’s optimized
protocol. For 293T cells, siRNA was transfected using Lipofecta-
mine 2000 (Invitrogen, Carlsbad, CA, USA). The siRNA target
sequence for N-CoR knockdown is 59AATGCTACTTCTC-
GAGGAAACA -39. siRNA targeting the luciferase sequence 59-
CGTACGCGGAATACTTCGA-39 was used as a control.
Dual luciferase reporter assay
Leukemic cell lines HL-60, THP-1, K562 and U937 were co-
transfected with 1 mg of Flt3 full-length promoter/firefly luciferase
reporter plasmid or promoter-less pGL3-basic vector (23) and 5 ng
of CMV/renilla luciferase plasmid by electroporation, using the
Cell Line Nucleofector Kit (Amaxa, Cologne, Germany). The cells
were harvested for luciferase assay, 48 hours post-electroporation,
as described by the Dual Luciferase Assay Kit (Promega, WI,
USA). 293T was co-transfected with 50 pmol of N-CoR-targeting
siRNA, 1 mg of Flt3 full-length promoter/firefly luciferase reporter
plasmid or promoter-less pGL3-basic vector, 5 ng of CMV/renilla
luciferase plasmid and various dosages of pAct-Flag/N-CoR or its
empty vector, using Lipofectamine 2000 (Invitrogen, Carlsbad,
CA, USA). The cells were harvested and reporter activity
determined 72 hrs post-transfection.
ChIP assay
Chromatin Immunoprecipitation (ChIP) was carried out with
the commercially available ChIP-IT kit (Active Motif, Carlsbad,
CA, USA) according to the manufacturer’s instructions. Prior to
precipitation, an aliquot of the chromatin was taken as input DNA
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3 mg of N-CoR [C-20] antibody (Santa Cruz Biotechnology, CA,
USA) or 3 mg of normal goat IgG (Santa Cruz Biotechnology, CA,
USA), as described by the kit’s manual. The purified immuno-
precipitated chromatin was subjected to RT-PCR analysis, using
the Accuprime Taq polymerase system (Invitrogen, Carlsbad, CA,
USA).
Proliferation of BA/F3 cells after N-CoR knockdown
BA/F3 cells transfected with either 2 mg of N-CoR siRNA or
2 mg of control siRNA via electroporation using the Amaxa Cell
line Nucleofector Kit V (Amaxa, Cologne, Germany). Cells were
allowed to recover in IL-3 containing growth medium for 48 hrs to
allow for Flt3 receptor expression. Cells were then washed in 16
PBS, and resuspended in IL-3 free culture medium or rm-Flt3
ligand (100 ng/ml) (R&D systems, MN, USA) supplemented
media. Cell growth was analyzed using the Cell Proliferation Kit I
[3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide;
(MTT)] (Roche, Germany) as described by the manufacturer.
The spectrophotometric absorbance was measured using a
microplate reader (Ultramark, Biorad, CA, USA) at wavelength
595 nm with a reference wavelength of 655 nm.
N-CoR status in rh-Flt3 ligand stimulated hFlt3 receptor
expressing 293T cells
293T cells were transfected with either 6 mg of MSCV-GFP-
Flt3 (WT) expression vector or 6 mg MSCV-GFP-Empty vector
and incubated for 24 hours. After which cells were serum starved
overnight and stimulated with 30 ng/ml of rh-Flt3 ligand for
4 hours before cells are assayed for SDS-PAGE and Western
Blotting Analysis.
Stabilization of N-CoR in rh-Flt3 ligand stimulated THP-1
cells
THP-1 cells were serum starved overnight and seeded at a
density of 4610
5 cells/ml in 3 mls of serum free media in a 6-well
plate. Anti-Flt3 antibody or control IgG was added in various
amounts (1, 0.5, 2.5,5 mg) and cells were incubated for 60 minutes
at 37uC in a humidified atmosphere of 5% CO2. Cells were then
stimulated with 30 ng/ml of rh-Flt3 ligand for 4 hours before
harvesting for protein expression analysis.
Cell Proliferation Assay
The cell proliferation assay was carried out using the Cell
Proliferation Kit I [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenylte-
trazolium bromide; (MTT)] (Roche, Germany) as described by the
manufacturer using cells treated at various concentrations of
Genistein for the stipulated treatment durations. The spectropho-
tometric absorbance was measured using a microplate reader
(Ultramark, Biorad, CA, USA) at wavelength 595 nm with a
reference wavelength of 655 nm.
Statistical analysis
The results of the proliferation assays were reported as mean 6
SD. Statistical analysis was performed using unpaired t-test. P
value less than 0.05 was considered to be statistically significant.
Cell differentiation assay
THP-1 cells treated with various concentrations of Genistein or
vehicle (DMSO) were collected and incubated with FITC-
conjugated monoclonal mouse anti-human CD14 antibody or
control IgG (Pharmingen, San Diego, CA) as per manufacturer’s
protocol. Antibody conjugated cells were analyzed using Fluores-
cence Activated Cell Sorting (NUMI core facility, National
University of Singapore).
For morphological analysis of THP-1 cells treated with
Genistein, cells were cytospun onto slides and stained with
Wright-Giemsa Stain and examined under light-microscopy.
Results
N-CoR loss correlates with the up-regulation of Flt3
expression
Previously our laboratory reported the role of N-CoR loss in the
pathogenesis of APL and restoration of N-CoR function via
Genistein, a tyrosine kinase inhibitor isolated from soy relieves the
block in differentiation and ultimately induced cell death [14,15].
Recently, we have also identified a similar APL-like post-
translational N-CoR loss in Acute Monocytic Leukemia (AML
of the M5 subtype in the French-American-British classification-
AML-M5). Given N-CoR’s documented importance in hemato-
poiesis and its role as a transcriptional co-repressor, we
hypothesized that N-CoR loss in AML-M5 cells may have altered
the expression profile of genes associated with the normal growth
and maturation of hematopoietic cells, eventually contributing to
malignant transformation. We therefore decided to identify the
hematopoietic genes which expressions could be affected by the
loss of N-CoR in AML-M5 cells.
Comparative Real-Time PCR analysis of 21 hematopoietic
genes [31] in 2 subsets of AML cells, the N-CoR positive cells, HL-
60 (a AML-M2 derived cell line) and U937 (a monocytic cell line
derived from histocystic lymphoma), and the 5 AML-M5 cells
namely THP-1, Nomo-1, Mono-Mac-1 (MM1), MV-4-11 and
SigM5 in which N-CoR was lost, identified Flt3 as the gene
selectively up-regulated in all AML-M5 cells (Fig. 1 and Fig. S1).
Analysis of more N-CoR positive and negative cells lines (Fig. 2A)
further established the inverse correlation between N-CoR status
and the level of Flt3 gene expression. The inverse correlation
between N-CoR and Flt3 expression was also found to be
translated to the protein level in the AML-M5 cell lines (Fig. 2B) as
well as in multiple histologically confirmed primary AML-M5
patient samples (Fig. 2C), where both the 130 kDa intracellular
non–glycosylated and the 160 kDa membrane bound glycosylated
forms were observed to be highly expressed. Furthermore, siRNA
mediated N-CoR knockdown performed on N-CoR positive HL-
60 revealed that after N-CoR ablation, Flt3 transcript levels was
significantly up-regulated while the levels of two other genes which
did not have a correlation with N-CoR status was not altered
(Fig. 2D left panel). Successful N-CoR knockdown in HL-60 cells
was determined via western blotting and RT- PCR (Fig. 2D
middle and right panel). Conversely, over-expression of Flag-
tagged N-CoR in THP-1 cells brought about a down-regulation of
Flt3 levels (Fig. 2E).
Flt3 is a transcriptional target of N-CoR
The inverse correlation between N-CoR and Flt3 expressions
suggested that the reduced Flt3 levels in cells which expressed
intact N-CoR protein might have resulted from a direct repression
of this gene by N-CoR. Therefore, to show that N-CoR was
indeed involved in the repression of Flt3, the activity of a luciferase
reporter driven by the full length Flt3 promoter was compared in
N-CoR positive and negative leukemic cells. The Flt3-luciferase
reporter activity was significantly lower in N-CoR intact HL-60,
K562 and U937 cells whereas in THP-1 cells, which lacked an
intact N-CoR protein, reporter activity was significantly higher
(Fig. 3A). Introduction of ectopic N-CoR in THP-1 cells (Fig. 3B,
left panel) resulted in a dose dependent reduction of Flt3 promoter
Flt3 Is a Transcriptional Target of N-CoR
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promoter was repressed by N-CoR, the effect of ectopic N-CoR
expression on Flt3 promoter activity was determined via luciferase
assay performed in 293T cells. In the initial experiments, it was
noted that despite repeated attempts, no significant reduction in
the Flt3 reporter activity by ectopic N-CoR was observed in 293T
cells (data not shown). Thinking that this lack of reduction in the
Flt3 reporter activity by ectopic N-CoR could be a result of the
high levels of endogenous N-CoR protein present in 293T cells,
the experiment was next repeated using N-CoR ablated 293T
cells. N-CoR ablation by N-CoR siRNA (Fig. S2) increased the
basal Flt3 reporter activity in 293T cells when compared to its
activity in non-ablated cells (Fig. 3C). Moreover, ectopic
restoration of N-CoR in N-CoR ablated 293T cells down-
regulated this augmented Flt3 promoter activity in a dose
dependent manner, and its value came down to a level that was
lower than the basal value (Fig. 3C). The degree of Flt3 promoter
inhibition by ectopic N-CoR was only two fold in N-CoR intact
293T cells irrespective of dose; while in N-CoR ablated cells, a
seven fold reduction was observed when N-CoR was introduced at
a maximum concentration of 1 mg (Fig. 3D). These observations
suggest an active role of N-CoR in the repression of the Flt3
promoter. Next, to validate that N-CoR suppression of Flt3
expression was via its binding to the Flt3 promoter region,
association of N-CoR protein with the promoter of Flt3 was
analyzed by chromatin immunoprecipitation (ChIP) assay. To
map the region of the Flt3 promoter specifically associated with N-
CoR, chromatin extracts of HL-60 or NB4 cells were immuno-
precipitated with anti-N-CoR antibody. The DNA co-precipitated
with N-CoR was amplified with primers flanking various regions
of the Flt3 promoter. Primers were designed to amplify DNA in
each of the following regions within the Flt3 promoter sequence,
more than 901 bps, between 614 bps to 814 bps and between
75 bps to 272 bps, upstream of the transcriptional start site. Only
the primers located in the 614 bps to 814 bps region upstream of
the transcriptional start site in the Flt3 promoter region (Fig. S3)
was able to amplify the DNA co-precipitated with N-CoR
antibody, suggesting that N-CoR and its associated repressor
complex may have bound to the Flt3 promoter through a region
located in that particular part of the promoter sequence (Fig. 3E).
CD36, a known N-CoR target gene, was used as a positive control
in this assay. Taken together, the data obtained so far indicates
that Flt3 repression may be brought about by the recruitment of
the N-CoR repressor complex to its promoter region and loss of N-
CoR in AML-M5 results in the subsequent loss of Flt3 gene
repression in these cells.
N-CoR loss promotes the IL-3 independent growth
potential of BA/F3 cells via the up-regulation of Flt3
Given the importance of Flt3 in the maintenance of survival and
proliferative capabilities of HSCs as well as leukemic blasts, we
hypothesized that aberrant expression of the receptor due to N-
CoR loss may be crucial in providing AML-M5 cells with a
survival and proliferative advantage. Thus in a proof of concept
approach, we utilized BA/F3 cells, an IL-3 dependent murine
bone marrow-derived cell line which expressed undetectable levels
of the Flt3 receptor and a high level of endogenous N-CoR in an
attempt to analyze the effects of N-CoR loss and Flt3 expression,
on the IL-3 independent growth properties of these cells. First N-
CoR levels were ablated in BA/F3 cells via siRNA mediated gene
knockdown and levels of Flt3 protein expression assessed via
western blotting with an antibody which was capable of detecting
the murine form of the Flt3 receptor. It was observed that in N-
CoR ablated BA/F3 cells; there was an increase in the level of
Figure 1. N-CoR loss is associated with the up-regulation of Flt3. A, Relative expressions of selected hematopoietic genes in AML-M5 and
non-AML-M5 (HL-60 and U937) cells were determined by real time PCR analysis. Data was analyzed via the comparative Ct method with the
expression level of each gene in HL-60 cells set as the reference value, and the level of expression of the HPRT gene used as the endogenous control.
The graph was plotted on a logarithmic scale with a base of 10. Expression levels in HL-60 cells for all genes were set to 0 while genes which were up-
regulated relative to their expression levels in HL-60 cells was given a positive value, and those which were down-regulated relative to expression
level in HL-60 cells were given a negative value. Raw Ct values that registered as undetermined were given a value of 40. (Results presented are the
averages of 3 independent experiments.).
doi:10.1371/journal.pone.0034501.g001
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3 independent growth properties of these N-CoR intact and N-
CoR ablated BA/F3 cells, in the presence and absence of the Flt3
ligand. It was observed that in the absence of IL-3, N-CoR ablated
BA/F3 cells had a slight proliferative advantage over non-ablated
cells. When stimulated with the Flt3 ligand, this proliferative
advantage was enhanced 2 fold. This suggests that N-CoR loss
promoted the IL-3 independent growth potential of BA/F3 cells
and this growth capacity could be potentiated by the activation of
the Flt3 signaling pathway via Flt3 ligand simulation (Fig. 4B).
N-CoR loss is potentiated by Flt3 signaling activation
With the observations in BA/F3 cells and our recent findings
which linked Akt activity to N-CoR loss (Nin et al, submitted
manuscript), we hypothesized that Flt3 activation by the Flt3
Figure 2. Flt3 expression is inversely related to N-CoR protein status. A, N-CoR and Flt3 levels in various human leukemia cells were
determined in western blotting and RT-PCR analysis respectively. B&C , Flt3 and N-CoR levels in AML-M5 derived cell lines (B) and in multiple
histologically confirmed human primary AML-M5 samples (C) were determined through western blotting assay using the respective antibodies.
Levels of N-CoR and Flt3 in HL-60 cells were used as a reference. D, Levels of Flt3, HoxA9 and Scl/Tal in HL-60 cells transfected with N-CoR or control
siRNA were determined by RT-PCR analysis (left panel). N-CoR knockdown efficiency at protein (middle panel) and transcript level (right panel) in HL-
60 cells transfected with N-CoR or control siRNA was determined through western blotting assay and RT-PCR analysis. E, Ectopic expression of Flag-
tagged N-CoR in THP-1 cells resulted in the loss of Flt3 expression as determine via western blotting assay with anti-Flt3 antibody. Levels of ectopic N-
CoR expression were determined via western blotting assay with anti-Flag antibody.
doi:10.1371/journal.pone.0034501.g002
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amplifying the growth advantage in AML-M5. To test this
hypothesis, we first tested the effect of Flt3 ligand stimulation on
the level of N-CoR protein in 293T cells in the presence or
absence of the Flt3 receptor. As shown in Figure 4C, Flt3 ligand
down-regulated N-CoR protein level in 293T cells in a Flt3
receptor dependent manner. To investigate if N-CoR loss in
AML-M5 cells was potentiated by Flt3 activation, we looked at the
effects of blocking Flt3 ligand-receptor interaction on the status of
N-CoR in THP-1 cells. Selective blockade of Flt3 ligand-receptor
binding with anti-Flt3 antibody led to the stabilization of N-CoR
protein in THP-1 cells in a dose dependent manner (Fig. 4D).
These data suggest that an oncogenic stimulus, which promotes
cellular growth through Flt3 activation could amplify Flt3
mediated survival by, further inducing N-CoR loss and receptor
expression up-regulation.
Restoration of N-CoR function by Genistein, down-
regulates Flt3, inhibits cell growth and induces terminal
differentiation of AML-M5 cells regardless of Flt3
receptor mutational status
Next, we decided to look at how the restoration of N-CoR
function in AML-M5 cells could affect the growth and
proliferative properties of AML-M5 cells expressing the Flt3 wild
type and/or mutant receptors. Utilizing Genistein, a drug which
we have previously shown to restore N-CoR native properties in
APL [15] and AML-M5 cells (Nin et al, submitted manuscript), we
first assessed the effect of Genistein induced stabilization of N-CoR
Figure 3. Repression of Flt3 by N-CoR protein. A, Relative activity of a luciferase reporter driven by the Flt3 promoter was determined in various
leukemic cell lines. The cells were transfected with reporter and reference plasmids using electroporation. The values presented in each bar represent
the average of three independent experiments. B, Effect of ectopic N-CoR on the activity of the Flt3 promoter in THP-1 cells electroporated with Flag-
tagged N-CoR plasmid in a dose dependent manner was determined via luciferase assay (left panel). The values presented in each bar represent the
average of three independent experiments. In parallel, levels of ectopic N-CoR protein in THP-1 cells used in the luciferase assay were determined in
western blotting assay with anti-Flag antibody (right panel). C, Effect of ectopic N-CoR on the activity of the Flt3 promoter in 293T cells transfected
with N-CoR or control siRNA was determined using luciferase assay. In pGL3-Flt3 (2901) reporter plasmid, luciferase reporter was placed under the
control of the full length Flt3 promoter. The values presented in each bar represent the average of three independent experiments. D, The dose
dependent fold repression by ectopic N-CoR in N-CoR ablated or non-ablated 293T cells was calculated by dividing the mean relative luciferase
activity in N-CoR siRNA transfected cells with that of control siRNA transfected cells of Fig. 3C. E, N-CoR is associated with the Flt3 promoter. Relative
amounts of Flt3 promoter sequence associated with N-CoR protein in HL-60 or NB4 cells were determined through ChIP assay. The antibody used in
the ChIP assay is mentioned at the bottom. N-CoR association with CD36 promoter, a known N-CoR target gene, was determined as positive control.
doi:10.1371/journal.pone.0034501.g003
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AML-M5 cell line THP-1 (a cell line reported to express the wild
type Flt3 receptor). It was observed that in THP-1 cells, Genistein
down-regulated Flt3 expression at both the transcript and protein
levels with maximum loss of expression occurring at 50 mM, the
dose which most effectively restored N-CoR protein expression
(Fig. 5A). Next we looked at the effect of N-CoR expression and
function restoration on the proliferative properties of THP-1 cells
via MTT assay. We noticed a dose dependent inhibition of the
growth capacity of treated cells. This inhibition was most
pronounced again at the dose of 50 mM (Fig. 5B). Morphological
analysis via Wright-Giemsa Staining of treated cells, revealed that
this growth inhibition was likely due to the relieve of differentiation
arrest as a significant number of Genistein-treated THP-1 cells
displayed characteristics of matured monocytic cells such as
horseshoe-shaped nuclei (Fig. 5C). Genistein induced differentia-
tion progression was further supported by the ability of Genistein
to up-regulate the level of CD14, a marker for myeloid/monocytic
lineage maturation in THP-1 cells in a dose dependent manner
when analyzed by FACS and RT-PCR analysis (Fig. 5D and E).
This suggested that Genistein induced growth arrest in THP-1
cells was likely due to the restoration of the ability of these cells to
Figure 4. N-CoR loss promotes growth potential, which is amplified by Flt3 signaling activation. A, Levels of N-CoR and Flt3 protein in
Ba/F3 cells transfected with control or N-CoR siRNA were determined via western blotting assay with an anti-Flt3 antibody that recognizes the murine
form of the receptor and anti-N-CoR antibody. B, N-CoR loss mediated Flt3 expression enhanced the IL-3 independent growth potential of BA/F3 cells.
Effect of IL-3 independent growth of Ba/F3 cells transfected with control or N-CoR siRNA (population from 4A) with and without Flt3 ligand
stimulation were determined by cell proliferation assay. The Y-axis of the graph represents the proliferation index of viable cells, and the durationo f
culture is plotted on the X-axis. The symbols used in the graph are as follows: Control siRNA transfected cells treated with vehicle ( ), Control
siRNA transfected cells stimulated with Flt3 ligand ( ), N-CoR siRNA transfected cells treated with vehicle ( ) and N-CoR siRNA transfected cells
stimulated with Flt3 ligand ( ). The values presented in each graph are average of three independent experiments. C, Flt3 stimulation leads to N-
CoR loss. Levels of N-CoR and Flt3 proteins in 293T cells treated with vehicle or Flt3 ligand (30 ng/ml) was determined by western blotting assay. D,
Blocking Flt3 stimulation leads to N-CoR stabilization in THP-1 cells. Effect of Flt3 antibody on the levels of N-CoR and Flt3 proteins in THP-1 cells
treated with vehicle or Flt3 ligand (30 ng/ml) was determined by western blotting assay.
doi:10.1371/journal.pone.0034501.g004
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order to determine if the restoration of N-CoR function had a role
in this progression in differentiation, we proceeded to knockdown
N-CoR via siRNA mediated gene knockdown in THP-1 cells and
looked at the ability of these cells to differentiate after Genistein
treatment. The expression level of the monocytic cell maturation
marker CD14 at the transcript level was used as an indicator for
progression of differentiation. It was observed that in the cells
where N-CoR was knocked down, there was no restoration of N-
CoR protein expression and function as Flt3 levels were not
reduced compared to the non-ablated cells. CD14 transcript levels
after Genistein treatment was also not significantly induced in the
N-CoR ablated cells (Fig. 5F), indicating that N-CoR function was
necessary in Genistein induced Flt3 down-regulation as well as the
growth inhibition and differentiation progression of THP-1 cells.
Next to investigate the effects of N-CoR function restoration on
the proliferative properties of AML-M5 cells expressing the
various mutants of the Flt3 receptor, the status of N-CoR after
Genistein treatment in a panel of AML-M5 cells (THP-1 and
Nomo-1- both expressing wild type Flt3, MM1- expressing a
constitutively active Flt3-TKD mutant due to an activating point
mutation at position 592 in the kinase domain, MV-4-11-
expressing the constitutively active Flt3-ITD mutant receptor
and Sig M5-no published reports on the status of the Flt3 receptor)
was assessed. After treatment with Genistein at 50 mM concen-
tration, it was observed that full length N-CoR was stabilized in all
5 AML-M5 derived cell lines and this was accompanied by the
observable down-regulation of the Flt3 receptor expression
regardless of the mutational status of the receptor in these cells
(Fig. 6A). Next, the effect of N-CoR function restoration on the
proliferative properties of these AML-M5 cells was investigated. It
was noted that Genistein inhibited the proliferative capacity of all
the N-CoR negative AML-M5 cells at the effective dose of 50 mM
while its growth inhibitory effect on the N-CoR positive HL-60
cells was less pronounced (Fig. 6B and C). Together, these
observations suggest that restoration of N-CoR function may be a
potential therapeutic strategy in restricting the contribution of the
Flt3 signaling pathway on the growth and proliferative properties
Figure 5. Restoration of N-CoR function in THP-1 cells, down-regulated Flt3 levels and induced differentiation. A, Flt3 levels were
down-regulated at both the protein and mRNA levels after Genistein treatment. Level of Flt3 expression was determined via western blotting and RT-
PCR analysis. B, Genistein inhibited the proliferation of THP-1 cells in a dose dependent manner when determined via growth proliferation assay
(MTT). Results are representative of 3 independent experiments and asterisks represent p,0.05. C, Nuclear morphology of THP-1 cells treated with
Genistein for the duration of 72 hours in a dose dependent manner was determined in Wright–Giemsa assay. The arrowheads mark the indented-
shaped nucleus of differentiated cells. D & E, CD14 levels in THP-1 cells treated with Genistein for 72 hours in a dose dependent manner was
determined by FACS (D) and RT-PCR (E) analysis. F, N-CoR, Flt3 and CD14 levels in THP-1 cells transfected with N-CoR siRNA and treated with 50 mM
Genistein for 72 hours was determined by western blotting assay and RT-PCR analysis.
doi:10.1371/journal.pone.0034501.g005
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mutational status.
Discussion
Our laboratory had previously reported the role of post-
translational N-CoR loss in the pathogenesis of APL [13,14,15].
The work presented in this manuscript was aimed at identifying
how the APL-like post-translational loss of N-CoR could
contribute to the pathogenesis of AML-M5 and to illustrate the
potential of N-CoR as a novel molecular target in AML-M5
therapy. Here we reported that Flt3 is a target of N-CoR mediated
transcriptional control. When this control is abolished due to post-
translational N-CoR loss, AML-M5 cells could reacquire the
capacities for growth and survival, which ultimately leads to
leukemogenesis in conjunction with other factors involved in
differentiation arrest. In normal cells, Flt3 is involved in the growth
of early progenitor cells and recent studies by Kikushige et al
reported that Flt3 expression in human HSCs, Granulocyte/
Macrophage Progenitor stages promoted and maintained cell
survival in these cells. This suggests that Flt3 has a critical role in
the survival of the stem and progenitor cells and present as
important targets for AML transformation [32]. N-CoR acts as a
co-repressor for various transcriptional factors and is not known to
bind directly to any specific DNA sequence. Therefore, it is not
clear if its association with the Flt3 promoter is direct, or mediated
indirectly by other DNA binding transcription factors. Although
the transcription factor binding sites at the proximal part of the
Flt3 promoter has been reported, there have been no studies
suggesting the existence of any similar sites in its distal and middle
regions. In the ChIP assay performed in this study, N-CoR was
found to be specifically associated with the 614 bps to 814 bps
upstream region of the transcriptional start site of the Flt3
promoter (Fig. S3). Identification of the factor that tethers N-CoR
to the Flt3 promoter through this particular region might be
crucial for the complete understanding of N-CoR’s role in Flt3
signaling and its implication leukemogenesis.
Although Flt3 activating mutations have been widely associated
with the poorer prognosis of AML patients, the fact that more than
70% of AMLs express wild-type Flt3 [24,33,34], implies that the
Figure 6. Restoration of N-CoR function attenuates the proliferative properties of AML-M5 cells regardless of the Flt3 receptor
mutational status. A, Genistein stabilized N-CoR in all 5 AML-M5 cell lines at 50 mM with a concurrent down-regulation of the Flt3 receptor
expression as determined via western blotting. B, Restoration of N-CoR function in AML-M5 cells attenuated the proliferative potential of AML-M5
cells. Proliferative capacity of N-CoR positive AML cells HL-60 and N-CoR negative AML-M5 cells after treatment with Genistein at 72 hours was
determined via growth proliferation assay (MTT). Growth inhibition was most pronounced at 50 mM in AML-M5 cells while at the same dose, growth
inhibitory effects on N-CoR positive HL-60 was less pronounced. Results are representative of 3 independent experiments and asterisks represent
p,0.05. C, Morphology of N-CoR positive HL-60 and N-CoR null AML-M5 cells (THP-1, Nomo-1, MV-4-11, SigM5, MM1) as determined via Wright-
Giemsa staining after treatment with 50 mM Genistein for 72 hours.
doi:10.1371/journal.pone.0034501.g006
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and proliferation of leukemic blasts. In our study, we found that N-
CoR regulates the expression of both the wild-type (THP-1 and
Nomo-1) as well as the activating mutants of Flt3 (MV-4-11:
FLT3-ITD, MM1: FLT3-TKDat position 592) as N-CoR loss and
reciprocal up-regulation of Flt3 gene expression was found
uniformly across all the AML-M5 cell lines used (There are no
known reports on the status of the Flt3 receptor in SigM5). We
also showed that knockdown of N-CoR in Ba/F3 cells resulted in
the aberrant expression of Flt3 and conferred a proliferative
advantage to Ba/F3 cells in IL-3 deficient conditions. With the
activation of the Flt3 signaling pathway in the presence of
activating factors, this IL-3 independent growth advantage was
enhanced, suggesting that the loss of N-CoR mediated Flt3
repression in AML-M5 may have resulted in the aberrant
expression of Flt3 and could enhance the survival and proliferation
of AML-M5 blasts in the presence of factors or mutations which
activate the Flt3 signaling pathway. Current therapies for AML-
M5 in clinical practice include aggressive multi-drug chemother-
apy, radiotherapy and allogenic bone marrow transplantations.
However these current strategies have severe side effects with high
morbidity rates. Flt3 inhibitors which target aberrant Flt3
activation in AMLs carrying the mutated Flt3 receptor have
recently gained prominence but their effectiveness on the wild-type
receptor is met with less success [35]; furthermore, resistance to
Flt3 inhibitors is an emerging drawback of Flt3 inhibitor based
therapy [36]. As many AMLs have been reported to express both
mutant and wild type Flt3 receptors, targeting a common factor
like N-CoR, which affects the expression of both receptors, could
present as a useful and novel therapeutic approach in AML-M5
treatment to address these drawbacks. Our laboratory has recently
identified various agents such as Genistein and Curcumin which
effectively target N-CoR loss in APL [15,37]. In this study, we
have shown that restoration of N-CoR function by small molecules
such as Genistein in AML-M5 cells effectively down-regulated Flt3
expression and reduced the growth capacity of these cells via the
induction of terminal differentiation regardless of the Flt3 receptor
mutational status. Recently, the molecular mechanism which
mediates N-CoR loss in AML-M5 have been elucidated in our
laboratory (Nin et al, submitted manuscript) and we have also
identified several small molecules which were able to target this
mechanism to restore N-CoR function and inhibit cellular growth
in AML-M5, suggesting that N-CoR could pose as a plausible
candidate for therapeutic targeting in AML-M5 independent of
the Flt3 receptor status.
Supporting Information
Figure S1 Relative expression of N-CoR protein in HL60, NB4
and THP-1 as determined via western blotting assay using anti-N-
CoR antibody (left panel). RT-PCR analysis of selected hemato-
poietic genes in AML-M5, APL and N-CoR expressing HL-60
cells. Only the Flt3 gene expression showed an inverse relationship
to N-CoR protein status in the cell lines used (right panel).
(TIFF)
Figure S2 N-CoR knockdown efficiency in experiments per-
formed in Fig. 3C was determined by RT-PCR. All siRNA, from
Qiagen, were synthesized as fully annealed oligonucleotide
duplexes. The lyophilized siRNA were processed as described by
the company’s instructions before used. For siRNA-mediated
knockdown of in 293T cells, siRNA was transfected into the cells
using Lipofectamine 2000 (Invitrogen) as described by the
manufacturer. The target sequence of siRNA used to knockdown
N-CoR was 59-AATGCTACTTCTCGAGGAAACA-39. A mock
siRNA targeting the luciferase sequence 59-CGTACGCGGAA-
TACTTCGA-39, not found in the mammalian genome, was used
as a non-specific control. 293T cell were transfected in 6-wells
plates with 50 pmol of each type of siRNA. 293T were harvested
72 hours post-transfection for verification of knockdown efficiency
by RT-PCT.
(TIFF)
Figure S3 Flt3 promoter sequence and ChIP primer priming
site. The Flt3 promoter sequence up to 2901 base pairs upstream
of the transcriptional start site in exon 1(highlighted). The putative
N-CoR binding region of the Flt3 promoter pulled down in ChIP
assay is marked by a red box. The forward and reverse primers are
indicated in bold font and grey highlights. The primers prime in a
region upstream of known transcription factor binding sites that
are indicated in black boxes. (Adapted from M.Inomata et al.
Leukemia Research 30 (2006) 659–664).
(TIFF)
Table S1 List of RT-PCR primers used in this study.
(DOC)
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